Dopamine receptor D-2 activation suppresses the radiosensitizing effect of aripiprazole via activation of AMPK
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hyounji | - |
dc.contributor.author | Kang, Seongman | - |
dc.contributor.author | Sonn, Jong Kyung | - |
dc.contributor.author | Lim, Young-Bin | - |
dc.date.accessioned | 2021-09-01T08:23:32Z | - |
dc.date.available | 2021-09-01T08:23:32Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2019-09 | - |
dc.identifier.issn | 2211-5463 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/63441 | - |
dc.description.abstract | Drug repositioning has garnered attention as an alternative strategy to the discovery and development of novel anticancer drug candidates. In this study, we screened 321 FDA-approved drugs against nonirradiated and irradiated MCF-7 cells, revealing that aripiprazole, a dopamine receptor D2 (D2R) partial agonist, enhances the radiosensitivity of MCF-7 cells. Unexpectedly, D2R-selective antagonist treatment significantly enhanced the radiosensitizing effects of aripiprazole and prevented aripiprazole-induced 5' adenosine monophosphate-activated protein kinase (AMPK) phosphorylation. Direct AMPK activation with A769662 treatment blunted the radiosensitizing effects of aripiprazole. These results indicate that aripiprazole has potential as a radiosensitizing drug. Furthermore, prevention of D2R/AMPK activation might enhance these anticancer effects of aripiprazole in breast cancer cells. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | BREAST-CANCER | - |
dc.subject | RADIATION-THERAPY | - |
dc.subject | DRUGS | - |
dc.subject | RADIOTHERAPY | - |
dc.subject | AGONIST | - |
dc.subject | CELLS | - |
dc.title | Dopamine receptor D-2 activation suppresses the radiosensitizing effect of aripiprazole via activation of AMPK | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Seongman | - |
dc.identifier.doi | 10.1002/2211-5463.12699 | - |
dc.identifier.scopusid | 2-s2.0-85069725208 | - |
dc.identifier.wosid | 000477331200001 | - |
dc.identifier.bibliographicCitation | FEBS OPEN BIO, v.9, no.9, pp.1580 - 1588 | - |
dc.relation.isPartOf | FEBS OPEN BIO | - |
dc.citation.title | FEBS OPEN BIO | - |
dc.citation.volume | 9 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1580 | - |
dc.citation.endPage | 1588 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.subject.keywordPlus | BREAST-CANCER | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | DRUGS | - |
dc.subject.keywordPlus | RADIOTHERAPY | - |
dc.subject.keywordPlus | AGONIST | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordAuthor | AMPK | - |
dc.subject.keywordAuthor | breast cancer | - |
dc.subject.keywordAuthor | dopamine receptor | - |
dc.subject.keywordAuthor | drug repositioning | - |
dc.subject.keywordAuthor | radiotherapy | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.